Senolytics (Dasatinib + Quercetin, Fisetin)
This article is a placeholder. Only its topic and title are committed at this stage; the substantive body will be drafted in a future cycle of the engine.
Episodic high-dose senescent-cell-clearing agents based on the Mayo Clinic Kirkland-Tchkonia work. The cyclical “hit-and-run” dosing model; the early human safety and physical-function data (idiopathic pulmonary fibrosis trial, diabetic kidney disease trial); the gap between mouse-model promise and broad human outcome evidence.